2018: Briefing note on NIH proposed license to Gilead for CD-30 CAR T technology

Contact: Kim Treanor 202-332-2670; kim.treanor@keionline.org January 5, 2018 The National Institutes of Health (NIH) has proposed an exclusive license with Gilead for certain patent applications for inventions that target CD-30 proteins and CAR T technologies. The proposed license is to… Continue Reading

EU Trade Commissioner Phil Hogan issues statement on European Union compulsory licensing in context of COVID-19, makes important statement about TRIPS Article 31bis

On 14 May 2020, Bernd Lange, Chair of the European Parliament’s Committee on International Trade (INTA) wrote a letter to Phil Hogan (Commissioner for Trade, European Commission) on the “commercial aspects of intellectual property rights for medical products in the… Continue Reading

AstraZeneca, Pfizer, IFPMA on the WHO COVID-19 Pool at May 28, 2020 IFPMA Press Briefing

At a May 28,2020 press briefing organized by the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA), pharma CEOs and the IFPMA DG commented on the WHO proposal for a global pool for rights in technologies for the diagnosis, prevention… Continue Reading

WHA73: Written statement of KEI – Agenda item 3 – Address by WHO Director-General devoted to the COVID-19 pandemic response in advance of the opening of the Health Assembly

KEI is an accredited non-state actor at the World Health Organization (WHO). This is our statement at the 73rd World Health Assembly. https://extranet.who.int/nonstateactorsstatements/meetingoutline/6 Knowledge Ecology International Meeting: Seventy-third World Health Assembly Written statements on COVID-19 pandemic The biggest question today… Continue Reading

WHO member states poised to adopt weaker than needed COVID-19 resolution after tortuous negotiations

UPDATE: The World Health Organization has published the COVID-19 response resolution as a conference paper (A73/CONF./1) marked with the date of 18 May 2020. The sponsors of the draft resolution included: Albania, Australia, Bahrain, Bangladesh, Belarus, Bhutan, Bolivia (Plurinational State… Continue Reading

Comments of Knowledge Ecology International Regarding “Purple Book Enhancement; Establishment of a Public Docket; Request for Comments” (FDA-2020-N-0437)

May 4, 2020 Comments of Knowledge Ecology International Regarding “Purple Book Enhancement; Establishment of a Public Docket; Request for Comments” (FDA-2020-N-0437) Knowledge Ecology International (KEI) provides the following comments regarding the Food and Drug Administration [FDA]’s Purple Book Enhancement. Our… Continue Reading